EGFR-c-MET Bispecific ADCs With Controlled Drug Loading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates (ADCs) with high drug loads exhibit faster clearance and lower maximum tolerated doses, narrowing therapeutic indices, while those with lower drug loads maintain favorable pharmacokinetic properties but may not deliver sufficient cytotoxic agents to targets effectively, particularly for EGFR and c-MET dual-targeting therapies.
Innovation Solution
Development of EGFR and c-MET bispecific binding agents and ADCs with controlled drug loading, utilizing specific amino acid sequences and linkers with polar groups to enhance targeting and intracellular delivery, achieving an average drug loading of about 1 to 16, optimizing pharmacokinetic properties and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If higher drug loads are used in ADCs, then more cytotoxic agent is delivered to target cells, but clearance from circulation increases and therapeutic index narrows
Solution Approach 1:
The patent applies local quality by attaching drugs to specific engineered sites at the N-terminus of light chains rather than random conjugation. This localized approach at specific amino acid positions (Asp1, Glu2, or Gln3) enables controlled drug loading (2-8 drugs per antibody) while maintaining favorable pharmacokinetic properties and therapeutic indices, resolving the contradiction between drug load and therapeutic reliability
Solution Approach 2:
The patent changes the parameter of drug loading from high (8-loads) to controlled low (2-8 loads per antibody) while improving pharmacokinetic properties. This parameter optimization demonstrates that moderate drug loads with engineered site-specific attachment achieve both sufficient cytotoxic delivery and acceptable therapeutic indices in animal models
2Quantity of substance
If higher drug loads are used in ADCs, then more cytotoxic agent is delivered to target cells, but clearance from circulation increases
Solution Approach 1:
By concentrating drug attachment at specific local sites (N-terminus of light chains at positions Asp1, Glu2, or Gln3) rather than distributed random conjugation, the patent achieves controlled drug loading that prevents excessive clearance. This localized quality control maintains circulation stability while delivering sufficient cytotoxic payload
3Reliability
If lower drug loads are used in ADCs, then favorable pharmacokinetic properties are maintained, but sufficient cytotoxic delivery to targets may not be achieved
Solution Approach 1:
The patent creates a universal engineered antibody platform with standardized light chain N-terminus sequences that can accommodate multiple different cytotoxic agents. This multi-functional design allows the same antibody scaffold to deliver various drugs (auristatins, maytansinoids, calicheamicins, etc.) at optimized loads, achieving both favorable pharmacokinetics and sufficient cytotoxic delivery across different therapeutic applications
Solution Approach 2:
The patent optimizes the drug load parameter to a moderate range (2-8 drugs per antibody) rather than extreme high or low values. This parameter optimization, combined with site-specific attachment, achieves the balance between maintaining pharmacokinetic properties and ensuring sufficient cytotoxic delivery to target cells
Data Source
AI summary
The present invention provides EGFR and c-MET bispecific antibodies, antigen binding portions thereof, other binding agents and EGFR and c-MET bispecific conjugates thereof, as well as methods and uses of such antibodies and conjugates for the treatment of cancer and autoimmune disease.